Press Releases – JDRF https://www.jdrf.org Improving Lives. Curing Type 1 Diabetes. Thu, 14 Mar 2024 14:20:10 +0000 en-US hourly 1 https://wordpress.org/?v=6.4.3 French Research Project, SFDT1, Receives Award from JDRF to Study Cardiovascular Risks in People with Type 1 Diabetes https://www.jdrf.org/press-releases/french-research-project-sfdt1-receives-award-from-jdrf-to-study-cardiovascular-risks-in-people-with-type-1-diabetes/ Thu, 14 Mar 2024 14:20:10 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185233 Paris, France, March 14, 2024—A French initiative called SFDT1 received an award from JDRF, the leading global type 1 diabetes (T1D) research...

The post French Research Project, SFDT1, Receives Award from JDRF to Study Cardiovascular Risks in People with Type 1 Diabetes appeared first on JDRF.

]]>
Paris, France, March 14, 2024—A French initiative called SFDT1 received an award from JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, to support its long-term study designed to explore and better understand cardiovascular risks and complications in people living with T1D. As one of the largest and most comprehensive studies of its kind, SFDT1 will follow a diverse group of 15,000 individuals living with T1D over 30 years, gathering a broad range of data that can help reduce complications and improve the quality of life for those with T1D.

Cardiovascular complications remain a dangerous risk for those living with T1D. People with T1D are several times more likely to experience cardiovascular events than those without T1D, even when common risk factors are not present. Through ongoing and regular engagement with participants, SFDT1 will collect and analyze clinical, psychosocial, and biological data as well as patient-reported outcomes and more that, over time, will provide insight into the key factors behind this increased risk. This cohort will seek to fill important gaps in T1D data, helping to create a more robust record of information that could potentially validate other research and inform future clinical trials.

“Reducing the risks of devastating complications of type 1 diabetes and improving the lives of those who live with the disease are key priorities for JDRF,” said Courtney Ackeifi, Ph.D., JDRF Senior Scientist. “While cardiovascular complications have been studied, it is not yet well understood why people with type 1 diabetes are at increased risk. The SFDT1 study presents the opportunity to gain a deeper understanding of cardiovascular risk that could pave the way for breakthroughs in treatment and ultimately improve the health of those who live with type 1 diabetes.”

The SFDT1 cohort will include adults and children over the age of six living with T1D and will be recruited from France and other French territories, allowing for diversity in participants.

 

About SFDT1 Study

SFDT1 is a research programme initiated by SFD (Société Francophone du Diabète) in 2019 and sponsored by the FFRD (Fondation Francophone pour la Recherche du Diabète). SFDT1 is a prospective, longitudinal cohort of people living with type 1 diabetes exploring factors associated with residual cardiovascular risk and other diabetes related complications. It will include 15000 participants (adults and children over 6 years old) with an active follow-up during 10 years and passive 30 years follow-up. For more information visit sfdt1.fr or follow us on Twitter (@SFDT1_fr) and Linked In (@e-cohorte SFDT1)

About SFD (Société Francophone du diabète)

SFD, Société Francophone du Diabète, was established in 1954. Its objective is to foster research development and quality clinical practice in diabetes in France and French speaking countries. This objective is translated in all activities, scientific meetings, research support, its main journal Diabetes & Metabolism and internet site. In addition, SFD is sponsoring the journal Médecine des maladies Métaboliques, MmM targeted to French speaking countries. Members, physicians and allied health care professionals, are all involved in research and diabetes care. For more information please visit sfdiabete.org

About FFRD ( Fondation Francophone pour la recherche sur le diabète)

A Foundation recognized as being of public utility to advance diabetes research. The Foundation has been established by the SFD with a single objective “to promote and support research in diabetes and metabolic diseases “ through public and private partnerships. For more information please visit ffrdiabete.org

About JDRF

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Type 1 Diabetes (T1D)
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

The post French Research Project, SFDT1, Receives Award from JDRF to Study Cardiovascular Risks in People with Type 1 Diabetes appeared first on JDRF.

]]>
JDRF Celebrates Women’s History Month with the Announcement of New International Board of Directors Chair https://www.jdrf.org/press-releases/jdrf-celebrates-womens-history-month-with-the-announcement-of-new-international-board-of-directors-chair/ Wed, 13 Mar 2024 13:00:27 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185208     Media Contact: Chelsea-Lyn Rudder media@jdrf.org 646-946-0513   Lisa Fishbone Wallack is an attorney by training and longtime JDRF volunteer The...

The post JDRF Celebrates Women’s History Month with the Announcement of New International Board of Directors Chair appeared first on JDRF.

]]>

 

 

Media Contact:
Chelsea-Lyn Rudder
media@jdrf.org
646-946-0513

 

Lisa Fishbone Wallack is an attorney by training and longtime JDRF volunteer

The global type 1 diabetes non-profit counts Fishbone Wallack’s parents among its founders

New York, March 13, 2024—In celebration of Women’s History Month, JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly announces the appointment of Lisa Fishbone Wallack as the new chair of the nonprofit’s International Board of Directors. Lisa, of Weston, Massachusetts, is an attorney by training and has volunteered with JDRF since childhood. Her brother was diagnosed with T1D as a toddler in 1969 and her son was diagnosed with the condition in 2001.

“I am excited and proud to welcome Lisa into her new role as chair of JDRF’s International Board of Directors,” said Aaron J. Kowalski, Ph.D., CEO of JDRF. “It is fitting for this news to be announced in March, which is Women’s History Month. Lisa is a dynamic leader with a deep connection to JDRF’s history and a strong vision for the organization’s future.”

Lisa has been a member of JDRF’s International Board of Directors since 2015. She previously served as the board’s vice chair and is a past president of JDRF’s Greater New England Chapter. Her appointment as chair continues a proud legacy of executive volunteer leadership at JDRF for Lisa’s family. Lisa’s parents, Marilyn and Dr. Gerald Fishbone, were among the organization’s founding families in the 1970s and her father served as chair of JDRF’s International Board of Directors in the 1980s.

“It’s an incredible honor to step into the role of chair of JDRF’s International Board of Directors,” said Lisa. “I have always had a special connection to JDRF through my family and am proud to work with the organization’s dedicated staff and passionate volunteers as we get closer to making cures for type 1 diabetes a reality.”

Lisa and her husband Neil have three children, Perry, Sydney, and Harris, who lives with T1D. She holds a B.A from the University of Pennsylvania and a J.D., summa cum laude, from the Benjamin N. Cardozo School of Law.

Lisa will be joined in her term of board leadership by Matt Varey, the newly appointed vice chair of JDRF’s International Board of Directors. Varey resides in Oakville, Ontario, Canada, and is a senior executive at Royal Bank of Canada.

###

About JDRF 

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes (T1D) and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Type 1 Diabetes (T1D) 

T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, including highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

 

 

 

The post JDRF Celebrates Women’s History Month with the Announcement of New International Board of Directors Chair appeared first on JDRF.

]]>
JDRF Proudly Announces the Appointment of New International Board of Directors Vice Chair https://www.jdrf.org/press-releases/jdrf-proudly-announces-the-appointment-of-new-international-board-of-directors-vice-chair/ Wed, 13 Mar 2024 13:00:13 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185210     JDRF International Media Contact: Chelsea-Lyn Rudder media@jdrf.org 646-946-0513 JDRF Canada Media Contact: Ruth Kapelus rkapelus@jdrf.ca 647.789.2322   Matt Varey of...

The post JDRF Proudly Announces the Appointment of New International Board of Directors Vice Chair appeared first on JDRF.

]]>

 

 

JDRF International Media Contact:
Chelsea-Lyn Rudder
media@jdrf.org
646-946-0513

JDRF Canada Media Contact:
Ruth Kapelus
rkapelus@jdrf.ca
647.789.2322

 

Matt Varey of Ontario is the first Canadian to serve as Vice Chair on the board of the global type 1 diabetes non-profit

New York and Toronto, March 13, 2024—JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, today announced the appointment of Matt Varey as the new vice chair of the non-profit’s International Board of Directors. Matt, of Oakville, Ontario, is the first Canadian and first person from outside of the United States to hold the vice chair position. He is a senior executive at Royal Bank of Canada, the country’s largest financial institution, where he is responsible for more than 4,500 Canada-based employees who manage personal investments, mortgage financing, and group benefits totaling more than $100 billion annually.

“It’s an exciting time at JDRF, filled with scientific breakthroughs and real opportunities to advance our mission, creating a world without type 1 diabetes”, said Aaron J. Kowalski, Ph.D., CEO of JDRF. “We are delighted that Matt is taking on the role of vice chair of JDRF’s International Board of Directors. I look forward to Matt’s partnership as we amplify JDRF’s work throughout the world.”

Matt has been a committed JDRF volunteer since 2001 and is an ardent supporter of JDRF’s efforts to find a cure for T1D and improving the lives of people living with the condition. In addition to his work on JDRF’s International Board of Directors, Matt serves on the board of JDRF Canada.

“I have been a JDRF volunteer for more than 20 years and am honored to step into the role of vice chair of JDRF’s International Board of Directors”, said Matt Varey. “I am excited to work in partnership with others around the globe to advance JDRF’s incredible purpose and to accelerate life-changing breakthroughs and cures for type 1 diabetes.”

Matt and his wife, Dr. Andrea Jack, are the parents to four adult children. He is a graduate of McMaster University in Hamilton, Ontario.

Varey will be joined in his term of board leadership by Lisa Fishbone Wallack, the newly appointed chair of JDRF’s International Board of Directors. Lisa is an attorney by training and resides in the Boston area.

###

About JDRF 

JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent, and treat type 1 diabetes (T1D) and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Type 1 Diabetes (T1D) 

T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, including highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

 

The post JDRF Proudly Announces the Appointment of New International Board of Directors Vice Chair appeared first on JDRF.

]]>
JDRF Celebrates the Renewal and Increase of the Special Diabetes Program https://www.jdrf.org/press-releases/jdrf-celebrates-the-renewal-of-the-special-diabetes-program/ Mon, 11 Mar 2024 16:13:10 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185168 JDRF applauds Congress for renewing and increasing the Special Diabetes Program (SDP), a critical program that now provides $160 million annually to...

The post JDRF Celebrates the Renewal and Increase of the Special Diabetes Program appeared first on JDRF.

]]>
JDRF applauds Congress for renewing and increasing the Special Diabetes Program (SDP), a critical program that now provides $160 million annually to type 1 diabetes (T1D) research through the National Institutes of Health. Congress also provided an equal amount to the SDP’s companion program – the Special Diabetes Program for Indians.

This renewal, which includes the first annual funding increase in 20 years and extends until December 2024, would not have been possible without our champions on Capitol Hill, including Senate Diabetes Caucus Co-chairs Senators Susan Collins (R-ME) and Jeanne Shaheen (D-NH) and Congressional Diabetes Caucus Co-chairs Representatives Diana DeGette (D-CO) and Gus Bilirakis (R-FL). It also would not have happened without tireless advocacy from the JDRF community, which includes 239 meetings with Members of Congress during the JDRF 2023 Children’s Congress this past summer, 368 more meetings held by JDRF Advocates as a part of our recent Promise to Remember Me campaign, and powerful testimony from JDRF CEO Aaron Kowalski, Ph.D. and JDRF 2023 Children’s Congress Chair, Natalie Stanback, in a hearing before the Senate Committee on Health, Education, Labor, and Pensions in December 2023. JDRF Advocates from all over the country also played a pivotal role, contacting Members of Congress thousands of times to let them know the importance of the SDP—and that it should be renewed.  

JDRF celebrates this renewal and increase and looks forward to continuing to partner with the National Institutes of Health to improve the lives of everyone affected by T1D and accelerate research breakthroughs to cure, treat and prevent it.  

 

March 11, 2024

 

Media Contact:
Chelsea-Lyn Rudder
media@jdrf.org
646-946-0513

The post JDRF Celebrates the Renewal and Increase of the Special Diabetes Program appeared first on JDRF.

]]>
JDRF Vice President of Research Esther Latres to Chair and Present at ATTD Session on Cell Replacement Therapy https://www.jdrf.org/press-releases/jdrf-vice-president-of-research-esther-latres-to-chair-and-present-at-attd-session-on-cell-replacement-therapy/ Fri, 08 Mar 2024 16:04:18 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185113 Contact: Casey Fielder 509-651-0087 media@jdrf.org   Media Advisory   On March 9, Esther Latres, Ph.D., vice president of research at JDRF, the...

The post JDRF Vice President of Research Esther Latres to Chair and Present at ATTD Session on Cell Replacement Therapy appeared first on JDRF.

]]>
Contact:

Casey Fielder

509-651-0087

media@jdrf.org

 

Media Advisory

 

On March 9, Esther Latres, Ph.D., vice president of research at JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, will chair and present at “Cell Replacement Therapy,” a session at the Advanced Technologies &Treatments for Diabetes (ATTD) international conference in Florence, Italy.

Dr. Latres’ presentation will address cell therapies as one of the most promising ways to cure T1D and will set the stage for the progress being made in research and future opportunities for cell therapies.

Following Dr. Latres’ introduction, the following researchers will share their insights:

  • Peter Senior: 20-year outcomes of islet cell transplantation – The benchmark for stem cells?
  • Jose Oberholzer: Islet cell replacement therapy for type 1 diabetes
  • Qizhi Tang: Engineering beta cells to enable immunosuppression-free replacement therapy for type 1 diabetes

The session will conclude with a round table discussion.

 

What: JDRF Vice President of Research chairs and presents at ATTD session on cell replacement therapy

Who: JDRF Vice President of Research, Dr. Esther Latres, Dr. Peter Senior, Dr. Jose Oberholzer, Dr. Qizhi Tang

When: Saturday, March 9, 2024, 11:30 a.m. – 1 p.m. CET

Where: Hall F, Fortezza da Basso, Viale Filippo Strozzi,1 50129 – Florence, Italy

 

 

The post JDRF Vice President of Research Esther Latres to Chair and Present at ATTD Session on Cell Replacement Therapy appeared first on JDRF.

]]>
JDRF Urges Congress to Advance Insulin Affordability Legislation Following 2024 State of the Union Address https://www.jdrf.org/press-releases/jdrf-urges-congress-to-advance-insulin-affordability-legislation-following-2024-state-of-the-union-address/ Fri, 08 Mar 2024 03:35:43 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185101 JDRF is pleased insulin affordability was raised by President Biden during tonight’s State of the Union address—an issue that continues to have...

The post JDRF Urges Congress to Advance Insulin Affordability Legislation Following 2024 State of the Union Address appeared first on JDRF.

]]>
JDRF is pleased insulin affordability was raised by President Biden during tonight’s State of the Union address—an issue that continues to have devastating consequences in the diabetes community. Recent progress, like the $35 monthly insulin copay cap for Medicare recipients included in the Inflation Reduction Act and voluntary price constraints implemented by pharmaceutical companies, are a step in the right direction. However, Congressional action is necessary to ensure everyone who needs insulin, regardless of insurance status, has access to this lifesaving medication at an affordable price. JDRF calls on Congress to advance the bipartisan INSULIN Act, led by Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), which would ensure insulin is affordable for the millions of Americans who need insulin every day to survive.  

 

March 7, 2024

Media Contact:  
Chelsea-Lyn Rudder
media@jdrf.org
646-946-0513

The post JDRF Urges Congress to Advance Insulin Affordability Legislation Following 2024 State of the Union Address appeared first on JDRF.

]]>
Early Check genome sequencing study reaches milestone of over 1,000 newborns screened in North Carolina https://www.jdrf.org/press-releases/early-check-genome-sequencing-study-reaches-milestone-of-over-1000-newborns-screened-in-north-carolina/ Mon, 26 Feb 2024 22:11:32 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=185010 The study screens newborns for hundreds of conditions using genome sequencing Research Triangle Park, N.C., Feb. 26, 2024 – Early Check, a...

The post Early Check genome sequencing study reaches milestone of over 1,000 newborns screened in North Carolina appeared first on JDRF.

]]>
The study screens newborns for hundreds of conditions using genome sequencing

Research Triangle Park, N.C., Feb. 26, 2024 – Early Check, a groundbreaking research study that provides free health tests to newborns up to four weeks old in North Carolina, today announced that it has screened over 1,000 newborns in the state under its genome sequencing study that launched in September.

The study screens for hundreds of childhood-onset rare genetic conditions, many of which are not identified through the state’s standard newborn screening, and assesses a newborn’s genetic risk of developing type 1 diabetes in their lifetime. Learning about risk for type 1 diabetes is optional with approximately 80% of parents choosing to receive this information.

“Early Check is giving parents vital information about their newborns that was previously not possible and allows them to get an early start on treatment plans when necessary,” said Holly Peay, Ph.D., a senior research scientist at RTI International and the project’s lead investigator. “Early Check is the first statewide research program to offer genome sequencing to newborns, so this marks an important milestone in North Carolina and nationally.”

To date, the study has identified 23 newborns at risk for rare genetic conditions, not including those at higher risk for type 1 diabetes. The newborns’ parents, following study protocol, have access to educational information and genetic counseling. Clinicians at the University of North Carolina at Chapel Hill School of Medicine also refer newborns to specialists across the state and contribute to the development of treatment plans as needed.

“For many patients, a genetic diagnosis only comes after years of living with often unexplained symptoms, ineffective treatments and incurring countless medical expenses,” said Paul Kruszka, M.D., Chief Medical Officer of GeneDx, which has been conducting the genomic screening and analysis. “By screening for and identifying these conditions at birth, we stop the odyssey before it even begins. We hope to see more states adopting similar programs, creating more opportunities for children and their families to have improved health outcomes.”

The most common finding has been G6PD deficiency, a genetic condition that is highly prevalent in North Carolina. G6PD affects an estimated 1 in 10 Black males. While G6PD does not always cause symptoms, some people with the condition, when exposed to certain chemicals, medications and foods, can experience serious symptoms and are advised to avoid triggering substances.

The study has also detected two babies at risk for nonsyndromic hearing loss and one at risk for a rare kidney disease that is associated with hearing and vision loss.

Not all conditions screened through Early Check can be prevented or treated and severity cannot always be determined via screening. For those conditions that have limited treatment options, education and early intervention may help prevent the worst outcomes in children.

Early Check is led by RTI and the University of North Carolina at Chapel Hill. The study offers additional newborn screening shortly after birth, under a research protocol, that supplements the standard newborn screening conducted in North Carolina. The additional screening is free and offered to newborns who are enrolled in the study by their parents when they are four weeks old or younger.

The Leona M. and Harry B. Helmsley Charitable Trust, JDRF International and Travere Therapeutics provided core funding for the expansion of the study, with additional support from Orchard Therapeutics.

GeneDx has been conducting the genomic screening and analysis using Illumina’s whole genome sequencing technology.

Learn more about Early Check and how to participate

The post Early Check genome sequencing study reaches milestone of over 1,000 newborns screened in North Carolina appeared first on JDRF.

]]>
JDRF Applauds Usher and NFL Star Noah Gray for Shining a Spotlight on Type 1 Diabetes at Super Bowl LVIII https://www.jdrf.org/press-releases/jdrf-applauds-usher-and-nfl-star-noah-gray-for-shining-a-spotlight-on-type-1-diabetes-at-super-bowl-lviii/ Mon, 12 Feb 2024 20:00:07 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=184878 Media Contact:   Kenya Felton  media@jdrf.org 646-385-0367  FOR IMMEDIATE RELEASE  More than 1.4 million Americans live with type 1 diabetes, an autoimmune disease...

The post JDRF Applauds Usher and NFL Star Noah Gray for Shining a Spotlight on Type 1 Diabetes at Super Bowl LVIII appeared first on JDRF.

]]>
Media Contact:  
Kenya Felton 
media@jdrf.org
646-385-0367 

FOR IMMEDIATE RELEASE 

More than 1.4 million Americans live with type 1 diabetes, an autoimmune disease that impacts people of all ages. People with T1D are dependent on injected or pumped insulin to survive. 

NEW YORK, NY, February 12, 2024 – JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, is recognizing Grammy award-winning megastar Usher and NFL Super Bowl Champion Noah Gray of the Kansas City Chiefs for shining a spotlight on T1D during Super Bowl LVIII.  

Usher’s now teenage son was diagnosed with T1D at just six years old. As Usher prepared for his highly anticipated Super Bowl Halftime Show and the release of his forthcoming album, he also prioritized raising awareness for T1D and the importance of screening. The music star spoke about his journey as the parent of a child with T1D and the need for greater knowledge and understanding about the disease in numerous media interviews in the run up to Super Bowl LVIII. 

“Usher’s advocacy has played a crucial role in raising awareness about type 1 diabetes and the importance of early detection through screening,” said Aaron Kowalski, CEO of JDRF. “Educating people about the symptoms of T1D and encouraging them to get screened can help reduce the risk of life-threatening complications and hospitalizations during diagnosis. Additionally, early detection gives families time to plan, prepare, and possibly benefit from a therapy that can delay the onset of type 1 diabetes. We cannot overstate the positive impact of Usher’s efforts.” 

Noah Gray, a standout tight end for the NFL Kansas City Chiefs, was diagnosed with T1D during his freshman year at Duke University. Determined to continue pursuing his dreams, Gray learned to manage his T1D and excelled academically and athletically. His hard work paid off when the Chiefs selected him in the 2021 NFL draft. Gray played a significant role in helping the team win the Super Bowl in 2023. Yesterday’s win against the San Francisco 49ers adds a second Super Bowl Championship to Gray’s resume. Gray is a shining example of how, with hard work and access to the tools that work best for them and their diabetes, individuals with T1D can train and compete in sports at every level. 

T1D is an autoimmune disease that affects more than 1.4 million Americans. The condition causes the pancreas to produce little or no insulin. People with T1D must carefully monitor their blood glucose levels and administer insulin to survive. T1D affects people at any age. There is currently no cure. 

Type 1 diabetes screening involves a blood test to check for specific autoantibodies that, if present, indicate that the body’s immune system is attacking the insulin-producing cells in the pancreas. Screening enables families to plan, prepare, and prevent severe complications like diabetic ketoacidosis (DKA) and hospitalization at the time of diagnosis. Early detection also opens the opportunity to receive a therapy to delay the onset of T1D or enroll in studies where other innovative therapeutic options may be available. 

T1Detect, JDRF’s education and awareness program for T1D risk screening, provides information on where to get screened and what to do after receiving the results. Visit JDRF.org/T1Detect to learn more. 

### 

About JDRF 
JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq). 

About Type 1 Diabetes (T1D) 
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, including highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D. 

The post JDRF Applauds Usher and NFL Star Noah Gray for Shining a Spotlight on Type 1 Diabetes at Super Bowl LVIII appeared first on JDRF.

]]>
Statement from JDRF calling for a Medical Corridor in the Middle East https://www.jdrf.org/press-releases/statement-from-jdrf-calling-for-a-medical-corridor-in-the-middle-east/ Mon, 12 Feb 2024 13:58:30 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=184790 JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, joins healthcare and humanitarian non-profits throughout the world in calling...

The post Statement from JDRF calling for a Medical Corridor in the Middle East appeared first on JDRF.

]]>
JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, joins healthcare and humanitarian non-profits throughout the world in calling for a medical corridor to allow immediate access to lifesaving supplies and medicines, like insulin, needed by all people living with T1D in the Middle East conflict zone. At all times, including times of conflict, people with T1D need insulin to live, regardless of race, religion, or national origin. JDRF urges those with influence in the region to aid in preserving life by joining our organization in supporting this effort.

 

February 12, 2024

The post Statement from JDRF calling for a Medical Corridor in the Middle East appeared first on JDRF.

]]>
JDRF Announces National Volunteer Award Recipients at Annual One Conference https://www.jdrf.org/press-releases/jdrf-announces-national-volunteer-award-recipients-at-annual-one-conference/ Wed, 07 Feb 2024 14:00:37 +0000 https://www.jdrf.org/?post_type=jdrf_press_release&p=184307     New York, Feb. 7, 2024—JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to...

The post JDRF Announces National Volunteer Award Recipients at Annual One Conference appeared first on JDRF.

]]>

 

 

New York, Feb. 7, 2024—JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to five outstanding volunteer leaders whose impact has pushed JDRF’s mission forward. The volunteers were recognized with the awards at JDRF’s annual One Conference on Feb. 6, 2024. Award recipients include:

  • Liz Chang, Carol and Erwin Lurie Award
  • Jennie Costner, Huntsman Family Community Engagement Award
  • Paul Heath, Jim Tyree Award
  • Margery Perry, Gerald Fishbone Award
  • Adam Singer, John Brady Award for Innovation

“For over 50 years, JDRF’s progress has been fueled by strong, passionate volunteer leaders,” said Aaron Kowalski, Ph.D., JDRF CEO. “It’s an honor to recognize the dedication and contributions of these five exceptional individuals and present them with these well-deserved awards. We extend our deepest gratitude for their commitment to JDRF’s mission and the broader type 1 diabetes community.”

Carol and Erwin Lurie Award
Named after Carol and Erwin Lurie, who helped found JDRF in 1970, the Carol and Erwin Lurie Award is presented to a chapter volunteer whose commitment to the volunteer/staff partnership has significantly advanced the mission and strategic priorities of JDRF over the past fiscal year. JDRF celebrates Liz Chang’s 10 years of dedicated service and unwavering commitment to raising funds for T1D research.

Liz and her family became involved with JDRF in 2013, shortly after her son was diagnosed with T1D. Since that time, she has made a tremendous impact serving in various roles within the Greater New England Chapter. She and her husband Joe served as the chapter’s 2023 gala honorees, and she currently serves as co-chair of the corporate development committee and co-captain of Team Agony of Duhfeet in the Ragnar Reach the Beach Relay. In addition, Liz is a former board president, board member, and nominating and board development committee member.

A consummate volunteer partner, Liz consistently builds strong relationships and galvanizes her personal and professional networks in support of a shared mission to accelerate life-changing T1D breakthroughs. Through her Ragnar Reach the Beach Relay team, Liz has raised more than $1 million for T1D research. She possesses an unparalleled passion for fundraising and played a pivotal role in the chapter’s record-breaking success at the 2023 gala. Liz’s relentless pursuit of a cure serves as an inspiration for those around her.

Huntsman Family Community Engagement Award
The Huntsman Family Community Engagement Award recognizes a volunteer who has made an impactful contribution to the T1D community by fostering a sense of community and engagement with the larger JDRF family and empowering individuals to make a difference in their own lives. JDRF honors Jennie Costner for her avid support of the T1D community, invaluable mentorship of advocacy team chairs, and exceptional leadership as national chair of the Grassroots Leadership Team.

Jennie became involved with JDRF in 2003, shortly after her daughter was diagnosed with T1D. She currently serves as a member of the Grassroots Leadership Team and advocacy pillar lead within JDRF’s Global Mission Board. She is actively involved in JDRF’s North Carolina Chapter, where she is a member of the board of directors and participates in outreach, fundraising, and awareness-raising activities.

In 2020, Jennie was asked to serve as the national chair of the Grassroots Leadership Team for JDRF Advocacy. Her impactful leadership was vital to the program’s success as she persevered with adaptability and strength during a time filled with uncertainty. Over the course of her tenure, Jennie mobilized and mentored leaders, improved uses of technology, and championed policy and legislation to support the T1D community, while leading with a mission-focused perspective. Jennie is a collaborative and inclusive volunteer partner, whose fearless direction and continued engagement have had a positive impact across JDRF and the T1D community.

Jim Tyree Award
The Jim Tyree Award recognizes a volunteer leader who has made a significant and noteworthy contribution to JDRF during their tenure of service. JDRF celebrates Paul Heath’s visionary leadership and groundbreaking contributions to the global T1D community.

Paul began his involvement with JDRF in 2012 after his daughter was diagnosed with T1D. He has worn many hats within the organization, both in JDRF Australia and JDRF International. Paul currently serves on the National Advocacy and Impact Committee and Directors Emeritus and is a former member of both JDRF International and JDRF Australia Boards of Directors. He has served as chair and vice chair of the JDRF Australia Board of Directors.

Paul’s service over the years has been wide-ranging and invaluable to JDRF and the T1D community. He provided guidance in setting global strategy and performed groundbreaking work on the T1D Index. Launched in 2022, the T1D Index broadly measures how many people live with the condition, the healthy years of life it takes from people living with T1D, and what can be done to reduce its impact, in every country around the world. As a champion of this work, Paul has counseled staff, obtained political support, and ensured that JDRF drives success with measurable outcomes. He was also key to overseeing JDRF International’s response to COVID-19. Paul’s unending commitment to a shared mission has been of great benefit to JDRF and the T1D community.

Gerald Fishbone Award
The Gerald Fishbone Award recognizes an individual for exemplary, long-term volunteerism in support of JDRF mission priorities. JDRF is proud to recognize Margery Perry with the inaugural Gerald Fishbone Award for her longstanding volunteerism, as well as her service on the JDRF Research Committee.

Margery became involved with JDRF in 1988 as a member of the San Diego Board of Directors shortly after her daughter was diagnosed with T1D. Margery currently serves as the research pillar lead for the Global Mission Board, member of the Directors Emeritus and Impact and Advocacy Committee, and as an advisor to the Research Committee.

Over the years, Margery’s passion and dedication to advancing T1D research led her to play key roles within JDRF, including as both member and chair of the Lay Review Committee, member of the JDRF International Board of Directors, and in the critical position of chair of the Research Committee. As chair of the Research Committee, Margery further solidified JDRF’s groundbreaking research initiatives and provided a steady hand during a time when it was needed. She is an advocate for clinical trial education and early detection of T1D and is passionate about the progress being made in T1D prevention and cures research.

John Brady Award for Innovation
The John Brady Award for Innovation recognizes an outstanding JDRF volunteer who has exhibited leadership in driving innovation and pioneering projects or ideas with the potential to meaningfully impact the T1D community. JDRF is proud to honor Adam Singer’s highly impactful leadership and contributions over the past 45-plus years.

Adam was diagnosed with T1D in 1978 at the age of 18 and became involved with JDRF’s chapter in Philadelphia shortly thereafter. During his early years with JDRF, Adam founded the organization’s first international division of support groups in 30 cities and served as a member of JDRF’s International Board of Directors from 1982 to 1985 as the youngest member in JDRF history. He chaired JDRF’s Facilities Committee and a task force to get diabetes supplies to Haiti following the 2010 earthquake. He is a long-time advocate and consistent leader, as well as a gala honoree and former board chair for the Mid Atlantic Chapter.

Markedly, one of Adam’s greatest contributions to JDRF’s mission is his founding of the JDRF Real Estate Games, a commercial real estate industry Olympics-style fundraising event. Since 1990, The Real Estate Games have raised more than $14 million for T1D research. This innovative event showcases Adam’s ability to cultivate relationships, connect people to JDRF’s mission, and drive fundraising. The Real Estate Games engage the commercial real estate communities in Washington, D.C., Chicago, and New York and have set an example of a wonderful industry partnership. The Washington D.C. event attracts more than 70 firms and 2,000 people. Adam is a dynamic volunteer partner who consistently puts the needs of JDRF and the T1D community first.

JDRF recognizes and appreciates all of the dedicated volunteers and supporters who commit their lives to the worldwide effort to end T1D.

About JDRF
JDRF’s mission is to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. To accomplish this, JDRF has invested more than $2.5 billion in research funding since our inception. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally and globally for efficiency and broader fundraising impact, and uniting on a global stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D. Our staff and volunteers throughout the United States and our five international affiliates are dedicated to advocacy, community engagement, and our vision of a world without T1D. For more information, please visit jdrf.org or follow us on Twitter (@JDRF), Facebook (@myjdrf), and Instagram (@jdrfhq).

About Type 1 Diabetes (T1D)
T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short or long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death if left untreated. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D.

###

 

Contact:
Casey Fielder
media@jdrf.org
509-651-0087

 

The post JDRF Announces National Volunteer Award Recipients at Annual One Conference appeared first on JDRF.

]]>